SAN MATEO, Calif.--(BUSINESS WIRE)--Bayhill Therapeutics Inc. announced today that it has entered into an exclusive worldwide license agreement for the development and potential commercialization of ...
Palo Alto, CA and New York, NY, October 30, 2008 – Bayhill Therapeutics, Inc., a leading developer of therapies for autoimmune diseases, and the Juvenile Diabetes Research Foundation, the world's ...
Strategies that restore immune tolerance are attracting growing interest in their potential to advance the treatment of type 1 diabetes beyond lifelong insulin therapy. Dan Jones investigates. In June ...
SAN MATEO, Calif. Bayhill Therapeutics announced its exclusive worldwide license agreement for the development and potential commercialization of BHT-3021 with Genentech. BHT-3021 is Bayhill’s ...
Milestone fees related to development, regulatory activities, and sales could exceed $325 million. Genentech is paying Bayhill Therapeutics $25 million up front in cash and equity for rights to its ...
you can get e-magazine links on WhatsApp. Click here Bayhill enters worldwide pact with Genentech for BHT-3021 in type 1 diabetes ...
Bayhill Therapeutics, Inc. and the Juvenile Diabetes Research Foundation has announced a partnership to support Bayhill’s ongoing Phase I/II human clinical trial of BHT-3021, a DNA vaccine to reverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results